您当前的位置：首页 > 研究体系 > 分子医学研究部

段　屹


dy.jpg

姓　　名:

段屹

地　　址:

安徽省合肥市蜀山区 中国科学技术大学 生命科学与医学部

邮　　编:

230027

电　　话:

0551-63607884

邮　　箱:

yduan@ustc.edu.cn



/uploads/image/2019/01/08/cfe1cd36d60b7f1c06e6497144a0d8cc.jpg

　教育与科研经历

2007-09 至 2011-06

中国科学技术大学，生物科学，学士

2011-08 至 2016-12

Texas A&M University, Biochemistry，博士

2017-03 至 2022-02

University of California at San Diego，博士后

2022-04 至今

中国科学技术大学，生命科学与医学部，教授


/uploads/image/2019/01/08/cfe1cd36d60b7f1c06e6497144a0d8cc.jpg

　目前研究方向

　　人体肠道内存在着超过1000种，与人体自身细胞数量相当的微生物种群。这一人体“最大的器官”，携带着百倍于人体自身基因数量的“第二套基因组”，在维持机体健康方面发挥着不可或缺的作用。
　　大量数据表明，肠道菌群失衡与多种人体疾病具备显著相关性。然而，进一步验证其因果性关系，发掘其背后的分子机理并为相关疾病的诊断治疗提供新靶点、新思路的高水平研究，还比较缺乏。深入探究肠道微生物在人体疾病中的作用，精准定位至具体菌株并详细阐明其致病机理，再据此开发以之为靶点的精准治疗手段，有着非常重要的科学价值和临床意义。课题组以此为出发点，旨在更好的揭示肠道微生物对人体疾病的影响，为新一代疾病诊疗突破及药物研发提供方向和思路。
　　具体研究方向如下：
　　1. 肠道微生物对代谢性及免疫性疾病的影响及其具体分子机制；
　　2. 微生物相关生物疗法，尤其是噬菌体疗法。


/uploads/image/2019/01/08/cfe1cd36d60b7f1c06e6497144a0d8cc.jpg

　代表性论文

1.

Duan Y#, Llorente C#, Lang S, Brandl K, Chu H, Jiang L, et al. (2019). Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 575(7783): 505-511. doi: 10.1038/s41586-019-1742-x.

2.

Xie S#, Li J#, Lyu F#, Xiong Q#, et al., Duan Y*, Jiang Y*, Zhou H*, Chen P*. (2023). Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis. Gut. 14(3):490. doi: 10.1136/gutjnl-2023-329996.

3.

Xingyao Chen#, Mendes BG#, Alves BS, Duan Y*. (2023). Phage therapy in gut microbiome. Progress in Molecular Biology and Translational Science. doi: 10.1016/bs.pmbts.2023.04.005.

4.

Mendes BG#, Duan Y#, Schnabl B. (2022). Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease. Viruses. 14(3):490. doi: 10.3390/v14030490.

5.

Duan Y, Young R, Schnabl B (2022). Bacteriophages and their potential for treatment of gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology. 19(2):135-144. doi: 10.1038/s41575-021-00536-z.

6.

Duan Y#, Chu H#, Brandl K, Jiang L, Zeng S, Mendes BG, et al. (2021). CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nature Communications. 12(1):7172. doi: 10.1038/s41467-021-27385-3.

7.

Chu H#, Duan Y#, Lang S, Jiang L, Wang Y, Llorente C, et al. (2020). The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease. Journal of Hepatology. 72(3):391-400. doi: 10.1016/j.jhep.2019.09.029.

8.

Gao B#, Duan Y#, Lang S, Barupal D, Wu TC, Valdiviez L, et al. (2020). Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis. Hepatology Communications. 4(8):1168-1182. doi: 10.1002/hep4.1537.

9.

Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, et al. (2023). Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 31(3):389-404. doi: 10.1016/j.chom.2023.02.001.

10.

Demir M#, Lang S#, Hartmann P#, Duan Y, Martin A, Miyamoto Y, Bondareva M, et al. (2022). The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology. 76(4):788-799. doi: 10.1016/j.jhep.2021.11.029.

11.

Hsu CL, Duan Y, Fouts DE, Schnabl B. (2021). Intestinal virome and therapeutic potential of bacteriophages in liver disease. Journal of Hepatology. 75(6):1465-1475. doi: 10.1016/j.jhep.2021.08.003.

12.

Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs L, et al. (2021). Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma. Cancer Discovery. 11(5):1248-1267. doi: 10.1158/2159-8290.CD-20-0304.

13.

Jiang L#, Lang S#, Duan Y, Zhang X, Gao B, Chopyk J, et al. (2020). Intestinal virome in patients with alcoholic hepatitis. Hepatology. 72(6):2182-2196. doi: 10.1002/hep.31459.

14.

Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al. (2020). Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 71(2):522-538. doi: 10.1002/hep.30832.

15.

Lang S#, Demir M#, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, et al. (2020). Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005.

16.

Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al. (2019). Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut. 68(8):1504-1515. doi: 10.1136/gutjnl-2018-317232.

17.

Chu H, Duan Y, Yang L, and Schnabl B (2019). Small Metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 68(2):359-370. doi: 10.1136/gutjnl-2018-316307.


相关文章